Reply

We thank Lipworth et  al1 for their correspondence regarding our article recently published in the Journal of Allergy and Clinical Immunology.2 We agree that it is currently unclear whether inhaled corticosteroid (ICS) use in chronic obstructive pulmonary disease (COPD) imparts an overall protective or detrimental effe ct on susceptibility to coronavirus disease 2019 (COVID-19). Theoretically, any potentially beneficial effects of ICS related to COVID-19, such as angiotensin-converting enzyme 2 attenuation and/or suppression of inflammation, could be offset by detrimental effects.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research